Document Detail

Safety and Feasibility of Combined Granulocyte Colony Stimulating Factor and Erythropoetin Based-Stem Cell Therapy Using Intracoronary Infusion of Peripheral Blood Stem Cells in Patients with Recent Anterior Myocardial Infarction: One-Year Follow-up of A Phase 1 Study.
MedLine Citation:
PMID:  21785174     Owner:  NLM     Status:  In-Data-Review    
Aim: to assess the safety and feasibility of combined granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) based intracoronary peripheral blood stem cells (PBSCs) therapy in patients with recent myocardial infarction (RMI) who had successful reperfusion therapy with drug-eluting stent. Methods: a total of 18 patients diagnosed with anterior ST-segment elevation AMI who had successful percutaneous coronary intervention (PCI) with drug-eluting stent implantation within 15 days after onset of symptom were enrolled. PBSCs were harvested and injected into the infarct-related artery after 5 consecutive days of G-CSF administration. Recombinant human erythropoietin was administered at the time of intracoronary PBSCs injection. Results: there were no procedural and periprocedural complications, such as ventricular arrhythmia, visible thrombus formation, distal embolization, injury of the coronary artery associated with the cell infusion catheterization procedure or elevation of CK-MB of more than two-times. After PBSCs injection, all patients had grade III myocardial blush grade. At follow-up of 21.1±5.5 months (range 12 to 30 months) there was no death, no re-infarction, no target lesion revascularization nor re-hospitalization for heart failure. Paired cardiac MRI demonstrated no change in left ventricular end-diastolic volume (LVEDV) and left ventricular end-systolic volume (LVESV) at 3 months, but they increased significantly at one year. Despite this, left ventricular ejection fraction (LVEF), wall motion score index (WMSI) and perfusion score index (PSI) improved at 3 months and remained stable at one year. The percentage of late gadolinium enhancement to LV mass (%LGE) were continuously improved until one year. There was no correlation between the level of CD34+, CD 45+, other cell subtypes as well as total number of PBSCs injected to the changes of LVEDV, LVESV, LVEF, WMSI, PSI, and %LGE (p >0.05). Conclusion: combined G-CSF and EPO based- intracoronary infusion of PBSCs in patients RAMI is safe and feasible.
Teguh Santoso; Cosphiadi Irawan; Idrus Alwi; Auda Aziz; Agus Kosasih; Sri Inggriani; Ardian Saputra; Merry Wintery; Linda Lison
Related Documents :
21311074 - Feline cerebrovascular disease: clinical and histopathologic findings in 16 cats.
22565144 - Patients with circumflex occlusions miss out on reperfusion: how to recognize and manag...
12639174 - Ramipril for the prevention and treatment of cardiovascular disease.
22812924 - Association between the amount of right-to-left shunt and infarct patterns in patients ...
11937074 - Cardiac markers of acute coronary syndromes: is there a case for point-of-care testing?
15100754 - Geographical location of residence and uniformity of access to cardiac revascularizatio...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Acta medica Indonesiana     Volume:  43     ISSN:  0125-9326     ISO Abbreviation:  Acta Med Indones     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-07-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7901042     Medline TA:  Acta Med Indones     Country:  Indonesia    
Other Details:
Languages:  eng     Pagination:  112-21     Citation Subset:  IM    
Department of Internal Medicine, University of Indonesia, Faculty of Medicine-Dr. Cipto Mangunkusumo Hospital. Jl. Diponegoro no. 71, Jakarta, Indonesia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The association between infection burden in Iranian patients with acute myocardial infarction and un...
Next Document:  Diagnosis and management of acromegaly: giant invasive adenoma.